The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
RAPAMYCIN: CLINICAL RESULTS AND FUTURE OPPORTUNITIES1
Abstract
INTRODUCTION Sirolimus (rapamycin; RAPA) is a macrocyclic lactone with a novel mechanism of immunosuppressive action (1). During the past 7 years, the drug has undergone clinical trials progressing from Phase I safety, tolerability, and pharmacokinetic investigation to Phase II dose-finding studies and limited-sized, multicenter evaluations of drug combination regimens. The completion of Phase III large randomized national and international trials led to approval of the drug to achieve augmented acute rejection prophylaxis in combination with cyclosporine (CsA) and steroids by the Food and Drug Administration of the United States in September 1999. In November 2000, the drug was approved by the European Agency as an alternate to calcineurin antagonists for long-term maintenance therapy. This overview seeks to familiarize the reader with the clinical information that provided the bases for drug approval and with the single-center reports that document alternate approaches to optimize the outcomes of treatment with this immunosuppressive agent. I. Update on Preclinical Findings RAPA, via its c-7 methoxy group (2), cross-links (3) the immunophilin FK binding protein (FKBP) 12, a peptide-prolyl isomerase that acts as a folding catalyst, to the multifunctional serine-threonine kinase, the mammalian target of rapamycin (mTOR) (4). Blockade of mTOR dampens lymphocyte responses to costimulatory signal 2 during the G0 to G1 transition and to cytokine signal 3 during the G1 build-up. By blocking the costimulation signals, RAPA prevents activation of the inhibitory factor kappa kinase necessary for generation of the c-Rel transcription factors of the NF-κB complex (5), and possibly also modulates protein kinase C activity (6). During the later G1 phase, by blocking signal 3, RAPA inhibits four cytokine-driven signaling pathways: a) p27kip1 degradation (7,8) leading to cyclin activation (9,10); b) p70S6 kinase stimulation, a step necessary for the synthesis of endosomal structural proteins (11–13); c) elongation factor 4A release from its association with PHAS-I, thereby facilitating ribosomal protein synthesis (14–16); and d) transcriptional up-regulation of the anti-apoptotic proteins bcl (17,18) and p21Ras (19) (Fig. 1). Both the therapeutic and the toxic effects of RAPA are related to the same cellular actions. The drug’s unique effects are complementary to calcineurin antagonists (CNAs) (20) and to interleukin-2 receptor monoclonal antibodies (anti–IL-2R mAbs); a relation that has been called the “cytokine paradigm”(21) (Fig. 2). Figure 1: Sites of enzyme action of mammalian target of rapamycin (mTOR). a) Activation of c-Rel factors downstream from reception of the costimulatory CD28 signal. b) Phosphorylation of p70S6 kinase preceding endosomal structural protein synthesis. c) Release of e-IH-4E from its association with PHAS-I, leading to the 4E activity necessary for elongation of the polypeptide chains on ribosomes. d) Dissociation of p27kip1 from cyclin C kinase, promoting cell division and up-regulated expression of bcl, an anti-apoptotic factor.Figure 2: The cytokine paradigm includes calcineurin antagonists (cyclosporine [CsA] or tacrolimus [TRL]) to block the antigen-driven signal 1 and RAPA to inhibit costimulatory signal 2, thereby mitigating transcriptional activation of cytokine synthesis during progression from G0 to G1. mAbs to IL-2R block the capacity of IL-2 to trigger signal 3 transduction events, which are inhibited by RAPA, preventing G1 progression (modified from reference 21).The preclinical development of RAPA has been extensively reviewed (22). After documentation of its immunosuppressive activity in animal models by the groups of Calne (23) and later by Morris et al. (24), RAPA was demonstrated to display a high degree of synergy with CsA both in vitro (25) and in vivo (26) by the rigorous median effect analysis. These findings provided the foundation for the drug’s initial clinical development in renal transplantation, anticipating that synergy with lower doses of CsA would not only more effectively prevent rejection, but also minimize CNA-induced toxicity. Two observations suggest other unique properties of RAPA that may be exploited in future controlled clinical trials. First, high doses of RAPA block the proliferative responses to cytokines by vascular and smooth muscle cells after mechanical injury, such as balloon angioplasty, or allorejection (reviewed in 27). In a nonhuman primate model, supratherapeutic concentrations of RAPA stabilized, and possibly reversed, the intimal vascular lesion caused by the progression of immune injury in aortic allografts (28). Studies are underway to assess the potential contributions of adjunctive agents to potentiate this effect at therapeutic levels of RAPA. Second, by virtue of its inhibition of bcl-2, RAPA may produce a tolerogenic pro-apoptotic effect, in apparent contradistinction to high doses of CNAs. RAPA treatment concomitant with mAb block
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
Liu, J., Farmer, J. D., Lane, W. S., Friedman, J., Weissman, I., & Schreiber, S. L. (1991) · Cell · doi:10.1016/0092-8674(91)90124-h · Cited by 4,116 · cited 4×
“002 4 (3) 17 (8) 19 (9) NS Thrombocytopenia 12 (8) 28 (10) 53 (20) 0.”
BackgroundInfluential
Cited by
Costanzo, M. R., Costanzo, M. R., Dipchand, A., Starling, R., Anderson, A., Chan, M., Desai, S., Fedson, S., Fisher, P., Gonzales-Stawinski, G., et al. (2010) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2010.05.034 · Cited by 1,653
Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
Eckardt, K.-U., Kasiske, B. L., & Zeier, M. G. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02834.x · Cited by 1,499
Calcineurin Inhibitor Nephrotoxicity
Naesens, M., Kuypers, D. R. J., & Sarwal, M. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04800908 · Cited by 1,489
Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells
Battaglia, M., Stabilini, A., & Roncarolo, M.-G. (2005) · Blood · doi:10.1182/blood-2004-10-3932 · Cited by 1,134
Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1
Wang, S., Tsun, Z.-Y., Wolfson, R. L., Shen, K., Wyant, G. A., Plovanich, M. E., Yuan, E. D., Jones, T. D., Chantranupong, L., Comb, W., et al. (2015) · Science · doi:10.1126/science.1257132 · Cited by 824
Metadata
- Authors
- Kahan, B. D., & Camardo, J. S.
- Venue
- Transplantation
- Published
- 2001-10
- Volume
- 72
- Issue
- 7
- Pages
- 1181-1193
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2052460475
- Cited by
- 225
- References
- 2
- FWCI
- 11.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RAPAMYCIN: CLINICAL RESULTS AND FUTURE OPPORTUNITIES1. https://app.cochat.ai/papers/10.1097/00007890-200110150-00001
- The paper
- Kahan, B. D., & Camardo, J. S. (2001). RAPAMYCIN: CLINICAL RESULTS AND FUTURE OPPORTUNITIES1. Transplantation. https://doi.org/10.1097/00007890-200110150-00001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.